Account
Inquiry
Tirzepatide 15mg is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist currently under development for type 2 diabetes treatment. This peptide demonstrates superior efficacy in glucose control and weight management compared to existing therapies.
The molecular structure of Tirzepatide 15mg features a lysine side chain with PEG modification, enhancing water solubility while maintaining biological activity. Clinical trials have shown significant weight loss results, with the 15mg dose demonstrating 20.9% average weight reduction after 72 weeks in the SURMOUNT-1 trial.
As a once-weekly injectable, Tirzepatide 15mg combines the effects of two incretin hormones into a single molecule, representing an innovative approach to metabolic disorder treatment. The peptide has received FDA Fast Track designation for obesity treatment applications.
For research purposes, we offer Tirzepatide 15mg in pharmaceutical grade purity (99.9%) with comprehensive analytical documentation. The product is supplied as white lyophilized powder in sterile vials with batch-specific certificates of analysis.
Storage conditions are critical for maintaining peptide stability. Tirzepatide 15mg should be kept in a cool, dry environment protected from light. Avoid repeated freeze-thaw cycles and prolonged exposure to air or solution.
This product is intended for research use only and not for human consumption. Researchers should follow all applicable laboratory safety protocols when handling Tirzepatide 15mg.
